Biogen Inc. (BIIB)

NASDAQ: BIIB · IEX Real-Time Price · USD
+5.25 (2.24%)
At close: Dec 7, 2023, 4:00 PM
-0.21 (-0.09%)
After-hours: Dec 7, 2023, 5:17 PM EST
Market Cap 33.89B
Revenue (ttm) 9.99B
Net Income (ttm) 1.46B
Shares Out 144.90M
EPS (ttm) 10.07
PE Ratio 23.75
Forward PE 16.42
Dividend n/a
Ex-Dividend Date n/a
Volume 1,221,270
Open 237.77
Previous Close 233.87
Day's Range 235.74 - 239.93
52-Week Range 220.86 - 319.76
Beta 0.08
Analysts Strong Buy
Price Target 326.52 (+36.55%)
Earnings Date Nov 8, 2023

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosi... [Read more]

Sector Healthcare
IPO Date Sep 16, 1991
Employees 8,725
Stock Exchange NASDAQ
Ticker Symbol BIIB
Full Company Profile

Financial Performance

In 2022, Biogen's revenue was $10.17 billion, a decrease of -7.36% compared to the previous year's $10.98 billion. Earnings were $3.05 billion, an increase of 95.80%.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for BIIB stock is "Strong Buy." The 12-month stock price forecast is $326.52, which is an increase of 36.55% from the latest price.

Price Target
(36.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts


Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment

Biogen Inc. BIIB, -1.21% on Wednesday reported third quarter results that topped analyst estimates, even as it navigates a complex launch of its new Alzheimer's treatment Leqembi.

4 weeks ago - Market Watch

Biogen cuts annual profit forecast on persistent higher costs

Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on rising costs related to the recent acquisition of rare disease drugmaker Reata Pharmaceuticals and the launch of i...

4 weeks ago - Reuters

Biogen Earnings Are Soon. What to Watch.

Wall Street will likely be more interested in updates on future developments, rather than the latest quarter's numbers.

4 weeks ago - Barrons

Biogen-Sage Therapeutics postpartum depression pill priced at $15,900

Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults is expected to cost U.S. wholesalers $15,900 for a full 14-day treatment, Sage Therapeutics said on Tuesday.

Other symbols: SAGE
4 weeks ago - Reuters

Biogen Appoints Monish Patolawala to its Board of Directors

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”...

4 weeks ago - GlobeNewsWire

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug.

6 weeks ago - Barrons

More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study

Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.

6 weeks ago - CNBC

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug.

6 weeks ago - Market Watch

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy...

6 weeks ago - GlobeNewsWire

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a fi...

Other symbols: RHHBY
6 weeks ago - Reuters

RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030

CNBC's Angelica Peebles reports on opportunities in the pharmaceutical sector.

Other symbols: LLYMRK
6 weeks ago - CNBC Television

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease (CTAD...

7 weeks ago - GlobeNewsWire

Final Trades: BIIB, XRT, TSLA & GILD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: XRTGILDTSLA
7 weeks ago - CNBC Television

Final Trades: WST, BIIB, SPY & MDT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: MDTSPYWST
2 months ago - CNBC Television

Biogen gets FDA approval for biotech treatment similar to Roche's Actemra

Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, or ...

2 months ago - Market Watch

FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formula...

2 months ago - GlobeNewsWire

Biogen Completes Acquisition of Reata Pharmaceuticals

CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeut...

2 months ago - GlobeNewsWire

Are Gene Therapy Stocks The Market's Next Big Winners?

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD...

2 months ago - MarketBeat

Japan approves Alzheimer treatment Leqembi by Eisai and Biogen

Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen.

2 months ago - Reuters

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massac...

2 months ago - GlobeNewsWire

Call of the day: The health care trade

CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.

3 months ago - CNBC Television

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., announced that it plans to conduct an observational, real-world study with Biogen (Nasdaq: BIIB) as the sponsor.

3 months ago - Business Wire

Biogen names Dr. Jane Grogan head of research effective Oct. 2

Biogen Inc. BIIB said Wednesday it has appointed Dr. Jane Grogan as head of research, effective Oct. 2. Grogan was most recently chief scientific officer at Graphite Bio, a cell and gene editing compa...

3 months ago - Market Watch

Biogen Appoints Jane Grogan as Head of Research

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023....

3 months ago - GlobeNewsWire